Literature DB >> 26378996

Evaluation of the quality of life in subjects with a history of severe anaphylactic reaction to the Hymenoptera venom.

Natalia Nowak1, Stanisława Bazan-Socha, Grażyna Pulka, Karolina Pełka, Paulina Latra.   

Abstract

INTRODUCTION: Sensitization to the Hymenoptera venom is one of the main causes of anaphylaxis in Poland. Venom immunotherapy is the only effective treatment in such cases. Comprehensive patient care includes also education. The aim of our study was to assess the state of knowledge and to evaluate the quality of life and the anxiety level in patients allergic to the Hymenoptera venom after anaphylactic reaction.
MATERIAL AND METHODS: The survey was carried out in the period of the insects flight in 61 adult subjects (35 wasp and 26 bee allergic), using a validated Vespid Allergy Quality of Life Questionnaire (VQLQ), Hospital Anxiety and Depression Scale, and subjective assessment of anxiety level. The majority of respondents received venom immunotherapy.
RESULTS: Sensitized to the wasp venom had significantly impaired quality of life (VQLQ score) as compared to the bee venom allergic (p = 0.014). The intensity of anxiety decreased with the duration of immunotherapy (p = 0.01). The majority of subjects knew how to recognize and treat anaphylaxis, but only 8% employed an identification card and about 50% implemented rules of the pre-exposition prophylaxis.
CONCLUSIONS: History of a severe anaphylaxis to the Hymenoptera venom affected the quality of life. Venom immunotherapy reduced anxiety. We hope that presented surveys and their results might be useful in qualifying for immunotherapy in clinically uncertain cases.

Entities:  

Keywords:  Hymenoptera; VQLQ; anaphylaxis; quality of life; venom immunotherapy

Mesh:

Substances:

Year:  2015        PMID: 26378996     DOI: 10.5603/PiAP.2015.0057

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  4 in total

Review 1.  Patient's Adherence and Compliance and Quality of Life During/After VIT.

Authors:  Cristoforo Incorvaia; Enrico Heffler; Silvia Peveri; Francesco Pucciarini; Giorgio Walter Canonica; Erminia Ridolo
Journal:  Front Allergy       Date:  2022-06-28

2.  Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-04-01       Impact factor: 1.837

3.  Fear of stinging insects in relation to state anxiety and trait anxiety in a group of patients with hymenoptera venom allergy undergoing immunotherapy.

Authors:  Agnieszka Woźniewicz; Ewa Szynkiewicz; Krzysztof Pałgan; Małgorzata Graczyk; Aneta Dowbór-Dzwonka; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

4.  Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy.

Authors:  Tamara Eitel; Kim Nikola Zeiner; Katharina Assmus; Hanns Ackermann; Nadja Zoeller; Markus Meissner; Roland Kaufmann; Stefan Kippenberger; Eva Maria Valesky
Journal:  World Allergy Organ J       Date:  2021-04-21       Impact factor: 4.084

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.